LAV Fund

What LAV Fund does

LAV Fund (Lilly Asia Ventures) is a biomedical venture capital firm that provides long-term capital and strategic support to entrepreneurs developing breakthrough healthcare products. Founded in 2008 as a corporate venture subsidiary of Eli Lilly and spun off to become an independent investment management company in 2011, LAV operates from offices in Hong Kong, Shanghai, and Menlo Park, California. The firm manages over $4.5 billion of committed capital with a team of more than 50 professionals experienced in science, medicine, investment, and operations, and maintains a portfolio of 70+ companies. Its investment scope spans biopharmaceuticals, human therapeutics, medical devices, and diagnostics.

LAV's core offering is direct equity investment into biomedical companies, typically as a participating (non-lead) investor that provides strategic decision support, executive recruitment, industry contacts, and business development resources alongside capital. Notable portfolio companies include IMPACT Therapeutics (HKEX-listed, Senaparib NMPA-approved), Alebund Pharmaceuticals (LAV-incubated, raised from Series B through Series C totaling over RMB 1.2 billion), Pulnovo Medical (Pulnovo PADN System), Syneron Bio (macrocyclic peptide platform partnered with AstraZeneca), Ronovo Surgical (surgical robotics partnered with J&J MedTech), Transcenta (HKEX-listed via IPO), ProfoundBio, ADARx, and ArriVent Biopharma. The firm co-invests with premier financial and strategic backers including Hillhouse, LYFE Capital, Decheng Capital, GL Ventures, Medtronic, and Johnson & Johnson JJDC.

LAV generates revenue through transaction-related economics on its investment portfolio, specifically capital gains on equity stakes realized through IPOs, acquisitions, and secondary transactions, augmented by management fees on committed capital. As a private venture capital fund, LAV does not publicly disclose financials, and its limited partner base is not disclosed in available materials. The firm's competitive position rests on biomedical domain expertise, a cross-border Asia-North America footprint, and a network of scientific advisors that supports deal sourcing and portfolio company development.

Name

LAV Fund

Legal name

Lilly Asia Ventures (LAV)

Website

https://lavfund.com

Company type

Private

Founded year

2008

Operating status

Operating

Short description

LAV Fund (Lilly Asia Ventures) is a biomedical venture capital firm providing long-term capital and strategic support to healthcare entrepreneurs. Managing over $4.5 billion across 70+ portfolio companies, LAV invests in biopharmaceuticals, therapeutics, medical devices, and diagnostics from offices in Hong Kong, Shanghai, and Menlo Park.

Ownership category

akta.pro rank

Product category

Biomedical Venture Capital

NAICS

Other Investment Pools and Funds (5259)

akta.pro primary industry

Venture Debt Providers (FSANAAAL)

Keywords

• Biomedical venture capital
• Life sciences investing
• Healthcare equity financing
• Biopharmaceutical investments
• Medical devices funding

Headquarters

HQ city

Sandhill

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Investment Returns: LAV generates returns through capital gains on equity investments in biomedical portfolio companies. Returns are realized through IPOs, acquisitions, and secondary transactions when portfolio companies exit.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

LAV Fund is a global biomedical venture capital firm providing long-term equity capital, strategic decision support, executive recruitment assistance, industry contacts, and business development opportunities to exceptional entrepreneurs building healthcare companies. The firm invests across biopharmaceuticals, human therapeutics, medical devices, and diagnostics, managing over $4.5 billion in committed capital.

Product overview

LAV Fund is a venture capital firm offering investment services to the biomedical and healthcare sector. Rather than a unified software platform with modules, LAV Fund provides venture capital funding, strategic guidance, and operational support to portfolio companies developing innovative therapies and medical technologies. The firm originated in 2008 as a corporate venture subsidiary of Eli Lilly and spun off to become an independent investment management company in 2011. Their investment scope spans biopharmaceuticals, human therapeutics, medical devices, and diagnostics, with a team of over 50 professionals experienced in science, medicine, investment, and operations.

Differentiator

Problem solved

Functional benefit

Products and services

• LAV Fund Venture Capital Investment Services

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Eli LillyfoundationalStrategic or Co-development Partner · 1 January 2008LAV originated in 2008 as a corporate venture subsidiary of Eli Lilly and spun off to become an independent investment management company in 2011. The firm maintains its biomedical focus and expertise rooted in its Lilly heritage.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• OrbiMed Advisors: Global healthcare-dedicated investment firm investing across biopharma, medical devices, and diagnostics. Directly comparable to LAV in its biomedical-only mandate and global geographic reach, though larger and more US-centric.
• Qiming Venture Partners: China-based VC with a substantial healthcare/biomedical practice investing in therapeutics, medical devices, and diagnostics. Closest China-domestic peer to LAV's biomedical focus and stage.
• Vivo Capital: Healthcare-focused investment firm with US-Asia operations investing across biopharma, medtech, and healthcare services. Comparable to LAV's cross-border healthcare mandate and similar AUM scale.
• ARCH Venture Partners: US-based venture firm focused on early-stage biomedical and life sciences companies. Comparable in its science-driven, therapeutics-focused investment approach, though primarily US-domestic.
• Lyfe Capital: Asia-based healthcare-dedicated investment firm. Directly comparable to LAV in healthcare focus and Asia geographic emphasis; co-led ProfoundBio Series A with LAV.
• Decheng Capital: China-focused life sciences investor backing therapeutics and medtech companies. Directly comparable in its healthcare/biomedical China focus; co-led Syneron Bio Series B with LAV.
• SR One (GSK): Biomedical-focused venture arm of GSK. Comparable to LAV's pharma-heritage origins (Eli Lilly) and its therapeutics-focused investing; led ADARx Series B alongside LAV.

Broad incumbents

• Hillhouse Capital: Large Asia-focused investment firm with a dedicated healthcare practice. Comparable in cross-border Asia-US investing and similar biomedical portfolio exposure, but operates a much broader multi-sector mandate.
• HongShan (formerly Sequoia Capital China): China-focused VC with a meaningful healthcare/biomedical practice. Overlaps with LAV in China healthcare investing, but operates a much broader consumer/tech mandate and larger AUM.
• CDH Investments: Large Chinese private equity firm with healthcare/biomedical investments. Comparable in China biomedical exposure (co-led Syneron Bio Series B with LAV), but operates a broader multi-sector mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LAV Fund